Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA) †
Titel:
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA) †
Auteur:
Ghesquieres, H. Chevrier, M. Laadhari, M. Chinot, O. Choquet, S. Moluçon-Chabrot, C. Beauchesne, P. Gressin, R. Morschhauser, F. Schmitt, A. Gyan, E. Hoang-Xuan, K. Nicolas-Virelizier, E. Cassoux, N. Touitou, V. Le Garff-Tavernier, M. Savignoni, A. Turbiez, I. Soumelis, V. Houillier, C. Soussain, C.